Skip to main content

GILEAD SCIENCES INC

For the period ended Dec 31, 2023. Filed Feb 23, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 23, 2024

GILD$169.32+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GILEAD SCIENCES, INC.
By:/s/ DANIEL P. O’DAY
Daniel P. O’DayChairman and Chief Executive Officer
Date:February 23, 2024

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel P. O’Day and Deborah H. Telman, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ DANIEL P. O’DAYChairman and Chief Executive OfficerFebruary 23, 2024
Daniel P. O’Day(Principal Executive Officer)
/s/ ANDREW D. DICKINSONChief Financial OfficerFebruary 23, 2024
Andrew D. Dickinson(Principal Financial Officer)
/s/ SANDRA PATTERSONSenior Vice President and Chief Accounting OfficerFebruary 23, 2024
Sandra Patterson(Principal Accounting Officer)
/s/ JACQUELINE K. BARTONDirectorFebruary 23, 2024
Jacqueline K. Barton, Ph.D.
/s/ JEFFREY A. BLUESTONEDirectorFebruary 23, 2024
Jeffrey A. Bluestone, Ph.D.
/s/ SANDRA J. HORNINGDirectorFebruary 23, 2024
Sandra J. Horning, M.D.
/s/ KELLY A. KRAMERDirectorFebruary 23, 2024
Kelly A. Kramer
/s/ KEVIN E. LOFTONDirectorFebruary 23, 2024
Kevin E. Lofton
/s/ TED W. LOVEDirectorFebruary 23, 2024
Ted W. Love, M.D.
/s/ HARISH MANWANIDirectorFebruary 23, 2024
Harish Manwani
/s/ JAVIER J. RODRIGUEZDirectorFebruary 23, 2024
Javier J. Rodriguez
/s/ ANTHONY WELTERSDirectorFebruary 23, 2024
Anthony Welters
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.